fda compounding semaglutide warning november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our The FDA has announced that

Cardiovascular Benefits Both Ozempic and Wegovy have been shown to have positive effects on heart health

Whilst GLP-1 receptor agonists are not licensed specifically as antihypertensive agents in the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved several formulations for glycaemic control and weight management

PMID 30061863.

Healthline reached out to Hims & Hers for comment, but did not receive a response

DISCUSSION This systematic review, conducted following PRISMA guidelines, evaluated the efficacy of retatrutide (LY3437943) in managing diabetes and obesity

Severe, persistent upper abdominal pain, with or without vomiting, should prompt urgent medical assessment